Researchers at Helius are exploring the vast potential of cannabinoids in treating pain, sleep, anxiety and other chronic conditions. Future targets will extend beyond symptom relief into disease modification, particularly in the treatment of inflammatory and neurodegenerative conditions.
As the country’s largest, vertically-integrated medical cannabis business, Helius is developing state-of-the-art, GMP-certified facilities in Auckland encompassing a large-scale cultivation centre, an integrated extraction site, advanced cannabinoid research laboratories and pharmaceutical manufacturing operations.
It holds a license to cultivate a prohibited plant for research purposes, including the cultivation of high THC cultivars.
The company recently purchased a 26-hectare greenfield site overlooking Lake Taupo to house its new facility, which will commence production in 2020 with an initial annual scaled production capacity of circa 17,000kg of dried flower for processing.
SETEK recently acquired a cannabis genetics company and a horticultural LED lighting company. Most recently, they signed a multi-year MoU with listed company, AFT Pharmaceuticals to work together in the research, development, commercialisation and distribution of cannabinoid-based medicines.
SETEK’s Advisory Board is headed by former Associate Health Minister, Hon Peter Dunne.